Baseline | Follow-up | p Value | |
Pre-bronchodilator FEV1 % predicted (259) | 66.4±23.7 | 72.7±26.8 | <0.001 |
Pre-bronchodilator FVC % predicted (242) | 82.7±20.3 | 86.5±21.5 | 0.002 |
Post-bronchodilator FEV1 % predicted (77) | 79.2±21.5 | 77.6±30.7 | 0.61 |
Post-bronchodilator FVC % predicted (72) | 90.6± 19.8 | 86.3± 25.9 | 0.08 |
Rescue oral steroids in previous 12 months (302) | 4 (2–6) | 2 (0–4) | <0.001 |
Hospital admissions in previous 12 months (324) | 0 (0–2) | 0 (0–1) | <0.01 |
Unscheduled visits in previous 12 months (315) | 4 (2–6) | 2 (0–6) | <0.05 |
Inhaled steroid dose, BDP equivalent (327) | 2000 (1000–2000) | 2000 (1200–2000) | 0.80 |
Average daily SABA use (205) | 6 (4–9) | 8 (4–10) | 0.058 |
Blood eosinophils (206) | 0.33 (0.11–0.60) | 0.20 (0.09–0.43) | <0.001 |
FeNO (112) | 40 (18–69) | 89 (77–102) | <0.001 |
Body mass index | 29.2±6.5 | 30.2±6.4 | <0.001 |
Group data (mean±SD or median (IQR)) for all subjects are presented in column 1 followed by data for individual centres. Comparisons were made using paired samples t tests or Wilcoxon signed rank tests; significance was taken as p<0.05.
BDP, beclometasone dipropionate; FeNO, fractional expiratory nitric oxide; FEV1, forced expiratory volume in 1 s; FVC, forced vital capacity; SABA, short-acting β agonist.